The field of bovine immunology has made significant strides in understanding the biology and function of T cells, which are crucial players in shaping ...
Dedifferentiated liposarcoma lacks effective IGF-1→PPAR-γ adipogenic signaling due to epigenetic silencing of PPAR-γ2, with ...
A new study has uncovered how an exceptionally scarce protein can orchestrate the assembly of large‑scale gene-silencing ...
Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) ...
UCB and Antengene enter global license agreement for ATG-201, a B cell-depleting bispecific antibody
UCB obtains worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune diseasesDeal ...
Company announces manufacturing readiness and financing extension ahead of first-in-human clinical studyLondon, United Kingdom, March 5, 2026, ...
Cullinan Therapeutics (NASDAQ:CGEM) executives highlighted multiple upcoming catalysts across the company’s oncology and autoimmune portfolio during a presentation at Citi’s Virtual Oncology ...
The International Society for Stem Cell Research (ISSCR) is pleased to announce that Alexander Meissner, Director at the Max Planck Institute for Molecular Genetics, Germany, has been named the ...
UCB has entered the red-hot T-cell engager (TCE) space by paying $80 million for the rights to a Chinese biotech’s preclinical autoimmune candidate. At the center of the deal is ATG-201, a CD19/CD3 ...
This insight explores the $1.1B primary cell market, highlighting how leaders like Lonza, Thermo Fisher, Cloud-Clone, ...
SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)--February 24, 2026-- ...
New findings from Karolinska Institutet reveal how the gene HNRNPU coordinates several fundamental molecular processes during ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results